Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of SAR444881 (formerly BND-22) in advanced solid tumors
MOH_2021-02-18_009734Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of BND-22 in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), gastric adenocarcinoma and 11 more (2 arms), sponsored by Sanofi. Started Nov 2020; status: recruiting.
02
Drugs
BND-22
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)gastric adenocarcinomagastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2021-02-18_009734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-18_009734.